培多普利抑制心肌重构的动物实验研究

目的:本研究采用Wistar大鼠冠脉结扎心梗后心衰模型,以培多普利作为观察药物,探讨肾素血管紧张素系统(RAS)在心肌重构中的地位和血管紧张素转换酶抑制剂(ACEI)对心肌重构的干预作用.方法:将Wistar大鼠分为梗塞组、梗塞治疗组和假术组.梗塞组结扎左冠状动脉,梗塞治疗组在前者基础上用培多普利治疗2mg/kg/天,假手术组不结扎左冠状动脉.三月后测血流动力学参数,血液及组织内血管紧张素Ⅱ(AngⅡ)含量、血管紧张素转换酶(ACE)活性和观察组织形态学变化.结果:三月后,与假术组相比,梗塞组出现了克血性心衰(DHF)的血流动力学改变;心肌局部AngⅡ含量、ACE活性显著差增高,但血液AngⅡ含量和ACE活性无明显改变;心脏重量指数显著上升;残存心肌细胞肥大,间质增生,胶原蛋白沉积.培多普利可以改善血流动力学参数,减少AngⅡ的生成、抑制ACE活性并减轻心肌细胞肥大、间质增生和胶原蛋白沉积的程度.结论:心肌组织局部的RAS参与了心肌重构的病理生理过程,血液RAS与心肌重构无显著相关,ACEI可以有效地防治心肌重构及心衰.

Experimental Study of peridopril Effect on inhibiting Cardiac Remodeling in Rats

Cardiac remodeling is a very important procedure, it plays a great tole in transition from remodeling to congestive heart failure(CHF) , so it appears significant to know how to inhibit it. Our study was to make use of cotonary ligated heart failure model of Wistar rets and take pendo-pril as expenmental drug in order to investigate the role of RAS in cardiac remodeling and the in-terention of ACE inhibitors with cardiac remodeling. Our result indicated that RAS plays a significant role in cardiac remodeling and ACE inhibitors can successfully inhibit the cardiac remodeling. We concluded that ACE inhibitors could be used as a kind of drugs in preventing and treating CHF.